Regeneron has announced new results from the phase 2 COURAGE trial evaluating trevogrumab (anti-GDF8/anti-myostatin) for its ...

In the third issue of The Vector, Genesis Research asked 15 payers across France, Germany, Italy, Spain, and the UK how they ...

Understanding how AI decisions are made, who owns the outcomes and how accountability travels across partners and platforms ...

Over the past decades, advances in information technology have fundamentally transformed the management of chronic diseases, ...

NSV is a chronic autoimmune disease where the immune system attacks melanin-producing cells, leading to a loss of pigment ...

Logistical challenges are not new in clinical research, from the high cost of developing new therapies to complexities in ...

AstraZeneca has announced the opening of its newest global strategic research and development (R&D) centre, in Kendall Square ...

At EHA 2026 in Stockholm, 425 hematologists and oncologists attended an independent, 90-minute Medscape symposium on the ...

Chiesi UK and Ireland has announced a new programme to help transform COPD diagnosis across the UK by providing NHS primary ...

The annual awards recognise excellence across 15 categories spanning innovation, manufacturing, sustainability and leadership ...

The results for litifilimab support the potential to achieve rapid and durable improvements in skin disease activity ...

This builds on a recently announced clinical collaboration between AstraZeneca and Summit to advance cancer treatments ...